Compare Merck & Co., Inc. (MRK) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Rockwell Automation — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while Rockwell Automation trades at $466.2 (market cap $51.04B). The key difference: Merck & Co., Inc. is far larger — about 6× Rockwell Automation's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | ROK | |
|---|---|---|
Market Cap | $307.25B | $51.04B |
Sector | Health | Industrials |
52-Week High | $129.52 | $495.08 |
52-Week Low | $77.60 | $328.67 |
Enterprise Value | $350.66B | $54.67B |
Dividend Yield | 2.73% | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Rockwell Automation (ROK) trades at $464.82, up 0.64% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 48.92% gross margin and 12.45% net margin, though valuation multiples like a 47.63 P/E appear elevated. Recent news highlights growth in industrial automation and AI infrastructure partnerships, including a contract with Aalo Atomics for nuclear reactor control systems (PRNewsWire, July 16, 2026).
Outlook is mixed: analyst consensus is a Buy with a $471.71 price target, but technical indicators suggest near-term pressure. Risks include margin compression and high debt levels, while opportunities lie in automation demand and new contracts. The stock offers a dividend yield of approximately 0.6% with consistent payouts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
